Compare NTAP & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTAP | UTHR |
|---|---|---|
| Founded | 1992 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5B | 25.1B |
| IPO Year | 1996 | 1999 |
| Metric | NTAP | UTHR |
|---|---|---|
| Price | $111.80 | $571.09 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 14 |
| Target Price | $116.58 | ★ $567.57 |
| AVG Volume (30 Days) | ★ 1.8M | 387.7K |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 22.46 | 13.07 |
| EPS | 4.32 | ★ 27.86 |
| Revenue | ★ $6,233,200,000.00 | $1,483,300,000.00 |
| Revenue This Year | $6.22 | $6.39 |
| Revenue Next Year | $4.91 | $14.18 |
| P/E Ratio | $25.69 | ★ $20.56 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $91.15 | $272.18 |
| 52 Week High | $126.66 | $607.89 |
| Indicator | NTAP | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 55.41 |
| Support Level | $102.22 | $560.16 |
| Resistance Level | $113.78 | $593.65 |
| Average True Range (ATR) | 3.02 | 12.17 |
| MACD | 0.64 | -2.95 |
| Stochastic Oscillator | 88.89 | 33.53 |
NetApp Inc is a provider of enterprise data management and storage solutions. The company's segments include Hybrid Cloud and Public Cloud. It generates maximum revenue from the Hybrid Cloud segment. The Hybrid Cloud segment offers a portfolio of storage management and infrastructure solutions that help customers recast their traditional data centers with the power of the cloud. This portfolio is designed to operate with public clouds to unlock the potential of hybrid, multi-cloud operations. Hybrid Cloud is composed of software, hardware, and related support, as well as professional and other services. Geographically, the company generates the majority of its revenue from the United States, Canada and Latin America (Americas).
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.